

# 293T Cyno PD-L1 Cell Line

Cat. No: KC-1001

Version 18102501

I.	Cell Line Information.....	1
II.	Background.....	1
III.	Cell Line Generation.....	1
IV.	Characterization using FACS.....	2
V.	Application.....	2
VI.	Cell Resuscitation.....	2
VII.	Cell Freezing.....	2
VIII.	References.....	3

## I. Cell Line Information

<b>Catalog number</b>	KC-1001
<b>Cell line name:</b>	293T Cyno PDL1 Cell Line
<b>Gene ID/Accession #:</b>	XM_005581779.2
<b>Host cell line</b>	293T
<b>Cell type:</b>	Human embryonic kidney
<b>Description:</b>	HEK293T cell line stable expressing exogenous cynomolgus PDL1 gene
<b>Quantity:</b>	One vial of frozen cells (5X10 <sup>6</sup> per vial)
<b>Stability:</b>	Stable in culture over a minimum of 10 passages
<b>Application:</b>	Drug screening and biological assays
<b>Freeze medium:</b>	70% DMEM + 20% FBS + 10% DMSO
<b>Propagation medium:</b>	DMEM + 10% FBS + 0.5ug/ml Puromycin
<b>Selection marker:</b>	Puromycin
<b>Morphology:</b>	Fibroblastoid cells growing as monolayer
<b>Subculture:</b>	Split saturated culture 1:4~1:5 every 2~3 days; seed out at about 1-3 x 10 <sup>5</sup> cells/ml
<b>Incubation:</b>	37 °C with 5% CO <sub>2</sub>
<b>Doubling time:</b>	Approximately 30 hours
<b>Mycoplasma status:</b>	Negative
<b>Biosafety level:</b>	1
<b>Storage:</b>	Liquid nitrogen immediately upon receiving

## II. Background

PD-L1, also called human programmed cell death ligand 1, is a transmembrane protein that play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease, virus infection and cancer. PD-L1 binds to its receptor PD-1 on activated T cells, B cells, and myeloid cells, to modulate activation or inhibition. Upregulation of PD-L1 can allow cancer cell to evade the host immune system.

### III. Cell Line Generation

293T cyno PD-L1 Cell Line was generated using lentivirus expressing cynomolgus PD-1 gene sequence.

### IV. Characterization using FACS




Figure: Characterization of PDL1 overexpressing in 293T stable clones using FACS.

### V. Application

- A. Hybridoma or binders of PD1/PD-L1 screening with FACS
- B. blockage of PD1/PD-L1 binding with FACS

### VI. Cell Resuscitation

1. Prewarm culture medium (DMEM supplemented with 10% FBS and 0.5ug/ml puromycin) in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0 mL complete culture medium.
5. Spin at ~ 125 x g for 5~7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO<sub>2</sub> incubator.
8. Split saturated culture 1:4 ~ 1:5 every 2~3 days; seed out at about 1-3 x 10<sup>5</sup> cells/ml.

### VII. Cell Freezing

1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.

3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least  $3 \times 10^6$  cells/ml in chilled freezing medium.
6. Aliquot 1 ml of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a  $-80^{\circ}\text{C}$  freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

## VIII. References

1. Sunshine, J. & Taube, J. M. PD-1/PD-L1 inhibitors. *Current Opinion in Pharmacology* 23, 32–38 (2015).
2. Bousiotis, V. A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. *N Engl J Med* 375, 1767–1778 (2016).
3. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 366, 2443–2454 (2012).

### **Kyinno Biotechnology Co., Ltd.**

Yizhuang Biomedical Park, No. 88, Beijing, China  
Tel: +86-10-58222702  
E-mail: [bd@kyinno.com](mailto:bd@kyinno.com)  
Web: [www.kyinno.com](http://www.kyinno.com)

**For Research Use Only**